Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE · Real-Time Price · USD
6.90
-0.35 (-4.83%)
Apr 1, 2026, 2:43 PM EDT - Market open
Wave Life Sciences Revenue
In the year 2025, Wave Life Sciences had annual revenue of $42.73M, down -60.55%. Wave Life Sciences had revenue of $17.25M in the quarter ending December 31, 2025, a decrease of -79.41%.
Revenue (ttm)
$42.73M
Revenue Growth
-60.55%
P/S Ratio
32.43
Revenue / Employee
$134,785
Employees
317
Market Cap
1.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 42.73M | -65.58M | -60.55% |
| Dec 31, 2024 | 108.30M | -5.00M | -4.42% |
| Dec 31, 2023 | 113.31M | 109.66M | 3,005.10% |
| Dec 31, 2022 | 3.65M | -37.32M | -91.09% |
| Dec 31, 2021 | 40.96M | 20.89M | 104.03% |
| Dec 31, 2020 | 20.08M | 4.09M | 25.61% |
| Dec 31, 2019 | 15.98M | 1.57M | 10.89% |
| Dec 31, 2018 | 14.41M | 10.52M | 270.25% |
| Dec 31, 2017 | 3.89M | 2.80M | 256.50% |
| Dec 31, 2016 | 1.09M | 940.00K | 618.42% |
| Dec 31, 2015 | 152.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Monte Rosa Therapeutics | 123.67M |
| Immatics | 56.67M |
| Taysha Gene Therapies | 9.77M |
| Precigen | 9.68M |
| AtaiBeckley | 4.09M |
WVE News
- 4 days ago - Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Phase I Data from INLIGHT Trial of WVE-007 for Obesity Transcript - Seeking Alpha
- 5 days ago - Wave Life Sciences stock crash: why analyst sees a buying opportunity - Invezz
- 6 days ago - Why Is Wave Life Sciences Stock Falling After Weight Loss Study Data? - Benzinga
- 6 days ago - WAVE LIFE SCIENCES Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 6 days ago - Wave Life Sciences shares plunge as data for high dose of obesity drug disappoints - Reuters
- 6 days ago - Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007 - GlobeNewsWire
- 26 days ago - FDA reversals leave investors worrying about the fates of other experimental drugs - CNBC
- 27 days ago - Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference - GlobeNewsWire